CAM Bioceramics

CAM Bioceramics is a contract development and manufacturing organization (CDMO) specializing in orthobiologic calcium phosphates for medical applications. Founded in 1985 as a spin-off from Leiden University in the Netherlands, the company pioneered the use of hydroxyapatite (HA) plasma-sprayed coatings on orthopedic implants in the 1980s, which became a global industry standard.

The company operates as a B2B partner, supplying its materials to industry leaders in the orthopedic, dental, spinal, and aesthetic sectors. Its business model is centered on the contract manufacturing, development, and engineering of calcium phosphate materials in various forms, including powders, granules, and blocks. These materials are used in applications such as implant coatings to improve osseointegration, bone graft substitutes, dermal fillers, and as excipients for drug delivery systems.

CAM Bioceramics offers highly customizable solutions, allowing clients to specify parameters like particle size, porosity, chemical composition, and degradation rate to meet precise market and product demands. The company maintains ISO 13485 certification and operates Class 7 cleanrooms to ensure its products meet stringent regulatory requirements for medical devices. In July 2023, German healthcare investor SHS Capital, along with ING Corporate Investments, acquired a majority stake to support and accelerate the company's future growth, with the existing management team remaining in place.

Keywords: calcium phosphate, contract manufacturing, orthobiologics, medical devices, hydroxyapatite, bioceramics, bone graft substitutes, dental implants, orthopedic coatings, implant coatings, CDMO, medtech, life sciences, plasma spray, tricalcium phosphate, biomaterials, dermal fillers, drug delivery excipients, ISO 13485